ArticleAmerican journal of respiratory and critical care medicine2012
The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hypertension.
Article in American journal of respiratory and critical care medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 121 papers, 13 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Interventions Against Insulin Resistance in Pulmonary Arterial Hypertension
Open the trial in the graphEvaluation of a New 6 Minute Walk Test Smartphone App in Patients With Pulmonary Hypertension (The 6-APP Study)
Evaluation of the Usefulness of Adopting Remote, Mobile-based 6MWT Among Hospital Outpatients (the 6-APPnow), Within the Constraints Imposed by the SARS-COV2 Pandemic
Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) Extension
Who cites it
121 citing papers in PubMed, 13 syntheses or guidelines pooled it, 271 citations in OpenAlex.
- Parenteral treprostinil in paediatric pulmonary arterial hypertension: a systematic review and meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2026Pooled it
- Effectiveness and safety of home-basedEuropean respiratory review : an official journal of the European Respiratory Society · 2025Pooled it
- Determining the minimum important differences for field walking tests in adults with long-term conditions: a systematic review and meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2025Pooled it
- Treatment of pulmonary arterial hypertension in patients with connective tissue diseases: a systematic review and meta-analysis.Internal and emergency medicine · 2024Pooled it
- Minimal Clinically Important Difference in the 6-minute-walk Distance for Patients with Pulmonary Arterial Hypertension.American journal of respiratory and critical care medicine · 2023Pooled it
- Exercise-based rehabilitation programmes for pulmonary hypertension.The Cochrane database of systematic reviews · 2023Pooled it
- Medications for the treatment of pulmonary arterial hypertension: a systematic review and network meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2022Pooled it
- Endothelin receptor antagonists for pulmonary arterial hypertension.The Cochrane database of systematic reviews · 2021Pooled it
- Exercise training for lung transplant candidates and recipients: a systematic review.European respiratory review : an official journal of the European Respiratory Society · 2020Pooled it
- Meta-analysis of use of balloon pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension.International journal of cardiology · 2019Pooled it
- Minimal clinically important difference for the 6-min walk test: literature review and application to Morquio A syndrome.Orphanet journal of rare diseases · 2017Pooled it
- Exercise-based rehabilitation programmes for pulmonary hypertension.The Cochrane database of systematic reviews · 2017Pooled it
- Pooled it
- Portable low-flow nasal oxygen versus ambient air in patients with chronic lung disease and exercise-induced hypoxaemia: a randomised controlled crossover non-inferiority trial.BMJ open respiratory research · 2026Trial
- Effect of a self-directed lifestyle-based weight management program among patients with comorbid COPD and sleep apnea: a secondary analysis of the INSIGHT COPD trial.Annals of the American Thoracic Society · 2026Trial
- Effect of Famotidine on Outcomes in Pulmonary Arterial Hypertension: A Randomized Controlled Trial.Chest · 2025Trial
- Dual intra-articular injections of corticosteroid and hyaluronic acid versus single corticosteroid injection for ankle osteoarthritis: a randomized comparative trial.BMC musculoskeletal disorders · 2025Trial
- The ALPHA phase 1 study: pulmonary ArteriaL hypertension treated with CardiosPHere-Derived allogeneic stem cells.EBioMedicine · 2024Trial
- Lifestyle Intervention and Excess Weight in Chronic Obstructive Pulmonary Disease (COPD): INSIGHT COPD Randomized Clinical Trial.Annals of the American Thoracic Society · 2023Trial
- Transcranial photobiomodulation therapy associated with cardiorespiratory rehabilitation in spastic subjects.Lasers in medical science · 2023Trial
61 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
rationaleAlthough commonly used as the primary outcome measure of clinical trials in pulmonary arterial hypertension (PAH), the minimal important difference (MID) of the 6-minute walk test (6MWT) has not been well defined for this population of patients.
objectivesTo estimate the MID in the 6MWT in patients with PAH.
methodsStudy subjects from the clinical trial of tadalafil in PAH, a 16-week, parallel-group, randomized clinical trial of patients who were treatment naive or on background therapy with an endothelin receptor antagonist, were eligible. 6MWT was performed using a standardized protocol. Distributional and anchor-based methods were used to estimate the MID; the latter method used the Physical Component Summary Score (PCS) of the Medical Outcomes Study 36-item short form (SF-36). MEASUREMENTS AND MAIN
resultsFour hundred five subjects were analyzed. Domains of the SF-36 were weakly to modestly associated with 6MWT. Change in the PCS of the SF-36 was most strongly associated with change in 6MWT (r = 0.40, P < 0.001) and thus was selected as the anchor for subsequent anchor-based analyses. Distributional analyses yielded estimates of the MID ranging from 25.1 to 38.5 m, whereas anchor-based analyses yielded an estimate of 38.6 m.
conclusionsUsing both distributional and anchor-based methods, the estimated consensus MID in the 6MWT for PAH is approximately 33 m. These results have important implications for (1) assessing treatment responses from clinical trials and metaanalyses of specific PAH therapy, and (2) sample size calculations for future study design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.